Compare LMAT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | RCKT |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 401.6M |
| IPO Year | 2006 | N/A |
| Metric | LMAT | RCKT |
|---|---|---|
| Price | $101.01 | $2.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $105.80 | $29.73 |
| AVG Volume (30 Days) | 210.9K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 30.57 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $249,602,000.00 | N/A |
| Revenue This Year | $14.21 | N/A |
| Revenue Next Year | $8.88 | $64.28 |
| P/E Ratio | $148.23 | ★ N/A |
| Revenue Growth | ★ 13.53 | N/A |
| 52 Week Low | $78.35 | $2.19 |
| 52 Week High | $118.01 | $6.83 |
| Indicator | LMAT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 29.72 |
| Support Level | $82.65 | N/A |
| Resistance Level | $114.98 | $3.52 |
| Average True Range (ATR) | 5.12 | 0.23 |
| MACD | -1.08 | -0.05 |
| Stochastic Oscillator | 26.42 | 1.42 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.